参考文献/References:
[1]Jain A,Kant R.Genotypes of erythrovirus B19, their geographical distribution & circulation in cases with various clinical manifestations[J].Indian J Med Res,2018,147(3):239-247.[2]Olejniczak M,Schwartz M,Webber E,et al.Viral Myocarditis-Incidence, Diagnosis and Management[J].J Cardiothorac Vasc Anesth,2020,34(6):1591-1601.[3]Fritch Lilla SA,Burgett SE,McGann KA,et al.Persistent and Prolonged Parvovirus B19 Viremia in a Pediatric Patient With Acute Lymphoblastic Leukemia[J].J Pediatric Infect Dis Soc,2015,4(3):e38-e40.[4]Pandey S.Human parvovirus B19 infection in an immunocompromised host[J].Clin Case Rep,2020,8(12):3610-3611.[5]Das P,Chatterjee K,Chattopadhyay NR,et al.Evolutionary aspects of Parvovirus B-19V associated diseases and their pathogenesis patterns with an emphasis on vaccine development[J].Virusdisease,2019,30(1):32-42.[6]Savkli AO,Cetin BA,Acar Z,et al.Perinatal outcomes of intrauterine transfusion for foetal anaemia due to red blood cell alloimmunisation[J].J Obstet Gynaecol,2020,40(5):649-653.[7]Obeid KM.Infections with DNA Viruses, Adenovirus, Polyomaviruses, and Parvovirus B19 in Hematopoietic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies[J].Infect Dis Clin North Am,2019,33(2):501-521.[8]Jain A,Jain P,Prakash S,et al.Prevalence of Parvovirus B19V in Hematological Malignancies and Chronic Anemia[J].Indian J Pediatr,2018,85(1):77-78.[9]Van Horn DK,Mortimer PP,Young N,et al.Human parvovirus-associated red cell aplasia in the absence of underlying hemolytic anemia[J].Am J Pediatr Hematol Oncol,1986,8(3):235-239.[10]Kelleher E,McMahon C,McMahon CJ.A case of parvovirus B19-induced pure red cell aplasia in a child following heart transplant[J].Cardiol Young,2015,25(2):373-375.[11]Lindblom A,Heyman M,Gustafsson I,et al.Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy[J].Clin Infect Dis,2008,46(4):528-536.[12]Kodidela S,Dorababu P,Thakkar DN,et al.Association of NUDT15*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia[J].Genes (Basel),2020,11(6):594.[13]Juhl D,Hennig H.Parvovirus B19: What Is the Relevance in Transfusion Medicine?[J].Front Med (Lausanne),2018(5):4.[14]Molenaar-de Backer MW,Russcher A,Kroes AC,et al.Detection of parvovirus B19 DNA in blood: Viruses or DNA remnants?[J].J Clin Virol,2016(84):19-23.[15]Juhl D,Gorg S,Hennig H.Persistence of Parvovirus B19 (B19V) DNA and humoral immune response in B19V-infected blood donors[J].Vox Sang,2014,107(3):226-232.[16]Kleinman SH,Glynn SA,Lee TH,et al.Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay[J].Transfusion,2007,47(10):1756-1764.[17]Majumdar S,Bean CJ,De Staercke C,et al.Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project[J].Transfus Med,2020,30(3):226-230.[18]Katragadda L,Shahid Z,Restrepo A,et al.Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease[J].Transpl Infect Dis,2013,15(4):354-360.[19]Ramesh A,Nakielny S,Hsu J,et al.Metagenomic next-generation sequencing of samples from pediatric febrile illness in Tororo, Uganda[J].PLoS One,2019,14(6):e0218318.[20]Kaya B,Paydas S.Recurrence of Pure Red Cell Aplasia in a Kidney Transplant Recipient Due to Reactivation of Parvovirus B19 Infection Despite Two Cycles of Intravenous Immunoglobulin Therapy[J].Exp Clin Transplant,2019,17(Suppl 1):195-197.[21]Crabol Y,Terrier B,Rozenberg F,et al.Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature[J].Clin Infect Dis,2013,56(7):968-977.[22]Bua G,Conti I,Manaresi E,et al.Antiviral activity of brincidofovir on parvovirus B19[J].Antiviral Res,2019(162):22-29.[23]Xu P,Ganaie SS,Wang X,et al.Endonuclease Activity Inhibition of the NS1 Protein of Parvovirus B19 as a Novel Target for Antiviral Drug Development[J].Antimicrob Agents Chemother,2019,63(3):e01879-18.[24]Eid AJ,Ardura MI,AST Infectious Diseases Community of Practice.Human parvovirus B19 in solid organ transplantation: Guidelines from the American society of transplantation infectious diseases community of practice[J].Clin Transplant,2019,33(9):e13535.[25]Feng S,Zeng D,Zheng J,et al.New Insights of Human Parvovirus B19 in Modulating Erythroid Progenitor Cell Differentiation[J].Viral Immunol,2020,33(8):539-549.[26]Zuffi E,Manaresi E,Gallinella G,et al.Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans[J].Viral Immunol,2001,14(2):151-158.[27]Ballou WR,Reed JL,Noble W,et al.Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1[J].J Infect Dis,2003,187(4):675-678.[28]Lowin T,Raab U,Schroeder J,et al.Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors[J].J Vet Med B Infect Dis Vet Public Health,2005,52(7-8):348-352.[29]Chandramouli S,Medina-Selby A,Coit D,et al.Generation of a parvovirus B19 vaccine candidate[J].Vaccine,2013,31(37):3872-3878.[30]Penkert RR,Young NS,Surman SL,et al.Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease[J].Vaccine,2017,35(29):3615-3620.[31]Ganaie SS,Qiu J.Recent Advances in Replication and Infection of Human Parvovirus B19[J].Front Cell Infect Microbiol,2018(8):166. [32]Russcher A,Enders A,de Brouwer CS,et al.Diagnosis of intrauterine parvovirus B19 infection at birth - Value of DNA detection in neonatal blood and dried blood spots[J].J Clin Virol,2020(129):104482. [33]Manaresi E,Gallinella G.Advances in the Development of Antiviral Strategies against Parvovirus B19[J].Viruses,2019,11(7):659. [34]Azevedo KM,Setúbal S,Camacho LA,et al.Parvovirus B19 seroconversion in a cohort of human immunodeficiency virus-infected patients[J].Mem Inst Oswaldo Cruz,2012,107(3):356-361. [35]Shehi E,Ghazanfar H,Fortuzi K,et al.A Rare Case of Parvovirus B19 Infection Manifesting as Chronic Aplastic Anemia and Neutropenia in a Human Immunodeficiency Virus-Infected Patient[J].Cureus,2020,12(12):e12174.[36]陆叶,胡绍燕,何海龙,等.苏州地区白血病儿童人微小病毒B19感染特点及预后分析[J].临床儿科杂志,2017,35(5):336-339.